Shelton Wealth Management LLC Invests $1.18 Million in Boston Scientific Corporation $BSX

Shelton Wealth Management LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,381 shares of the medical equipment provider’s stock, valued at approximately $1,181,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Steph & Co. bought a new position in shares of Boston Scientific during the 3rd quarter worth about $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp boosted its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth about $26,000. Finally, United Community Bank boosted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Announced an $88.4M investment to expand R&D capacity in Ireland — a move that strengthens product development, secures engineering capacity in a low‑tax jurisdiction, and supports longer‑term pipeline and revenue growth. Boston Scientific invests $88.4M to expand R&D in Ireland
• Positive Sentiment: Analysts are bullish on BSX, pointing to expectations of roughly 30% year‑over‑year growth in 2026 — a narrative that can support multiple expansion and buying interest if guidance/earnings validate those trends. Analysts Bullish on Boston Scientific (BSX) Amid Expectations for 30% YoY Growth in 2026
• Positive Sentiment: Pre‑earnings coverage (Zacks/others) highlights potential for an earnings beat given momentum in procedure volumes and the company’s recent beat and raised guidance history — a catalyst that could lift shares on a positive report. Boston Scientific (BSX) Outperforms Broader Market: What You Need to Know
• Neutral Sentiment: Truist trimmed its price target slightly (from $92 to $90) but kept a Buy rating — a modest near‑term negative signal, but still indicates analyst confidence in upside over the medium term. Benzinga: Truist lowers price target
• Neutral Sentiment: Industry deal activity: AIP’s acquisition of Avanos (a competitor in some product areas) shows consolidation in related medtech segments — monitor competitive dynamics but this is not an immediate company‑specific earnings driver. AIP to acquire Avanos Medical in $1.27B go-private deal
• Negative Sentiment: Multiple law firms have filed or solicited clients in a securities class action alleging BSX misled investors about U.S. electrophysiology procedure growth (class period July 23, 2025–Feb 3, 2026); firms are seeking lead plaintiffs with a May 4 deadline — this raises legal/financial overhang and can pressure the stock while exposure is uncertain. BSX INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action ROSEN Law Firm investor alert

Boston Scientific Price Performance

Shares of NYSE BSX opened at $63.42 on Friday. Boston Scientific Corporation has a fifty-two week low of $60.59 and a fifty-two week high of $109.50. The stock has a market cap of $94.25 billion, a price-to-earnings ratio of 32.69, a PEG ratio of 1.00 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm’s 50-day simple moving average is $69.84 and its 200 day simple moving average is $87.19.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the firm earned $0.70 EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. Evercore dropped their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $115.00 price target on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $102.82.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.